Conference
Phase 1/2 Clinical Study of VRDN-001, A Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients with Thyroid Eye Disease (TED) (P3-9.001)
Authors
Moster M; Douglas R; Cockerham K; Turbin R; Nijhawan N; Schiffman J; Ugradar S; O’Shaughnessy D; Summerfelt R; She A
Volume
100
Publisher
Wolters Kluwer
Publication Date
April 25, 2023
DOI
10.1212/wnl.0000000000202314
Conference proceedings
Neurology
Issue
17_supplement_2
ISSN
0028-3878